Clinical features of VITT associated with AZ and J&J vaccines
| Features . | UK cases7 . | US cases5 . |
|---|---|---|
| Total no. of cases | 309 | 28 |
| Total no. of vaccines administered, million | 32.9 | 8.7 |
| Reporting rate, per million | 9.4 | 3.2 |
| No. after first-dose vaccine (%) | 294 (95) | 28 (100) |
| Female (%) | 169 (55) | 22 (78) |
| Age range, y | 18-93 | 18-59 |
| No. of patients <50 y (%) | 129 (42) | 22 (78) |
| No. of patients <70 y (%) | 254 (82) | 28 (100) |
| CVT (%) | 116 (38) | 19 (68) |
| ICH (%) | NR | 10 (36) |
| Death (%) | 56 (18) | 3 (11) |
| Features . | UK cases7 . | US cases5 . |
|---|---|---|
| Total no. of cases | 309 | 28 |
| Total no. of vaccines administered, million | 32.9 | 8.7 |
| Reporting rate, per million | 9.4 | 3.2 |
| No. after first-dose vaccine (%) | 294 (95) | 28 (100) |
| Female (%) | 169 (55) | 22 (78) |
| Age range, y | 18-93 | 18-59 |
| No. of patients <50 y (%) | 129 (42) | 22 (78) |
| No. of patients <70 y (%) | 254 (82) | 28 (100) |
| CVT (%) | 116 (38) | 19 (68) |
| ICH (%) | NR | 10 (36) |
| Death (%) | 56 (18) | 3 (11) |
CVT, cerebral vein thrombosis; ICH, intracerebral hemorrhage; NR, not reported; UK, United Kingdom; US, United States.